TAK 816

Drug Profile

TAK 816

Alternative Names: CRM-Hib vaccine conjugate - Novartis; Hib-CRM197 vaccine conjugate - Novartis; Monovalent Hib vaccine - Novartis; PRP-CRM197 conjugate Hib vaccine - Novartis; TAK-816; Vaxim Hib

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Chiron
  • Developer GlaxoSmithKline
  • Class Haemophilus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Haemophilus infections

Most Recent Events

  • 09 May 2017 GlaxoSmithKline terminates licensing agreement with Takeda for TAK 816 in Japan
  • 22 Jan 2016 Registered for Haemophilus infections (In infants, Prevention) in Japan (IM)
  • 01 Mar 2015 Takeda completes a phase III trial for Haemophilus infections (in infants, prevention) in Japan (NCT02074345)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top